{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urinary-tract-infection-children/prescribing-information/nitrofurantoin/","result":{"pageContext":{"chapter":{"id":"178d0dc1-f68e-5c02-8ab6-590182cdb89b","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin","depth":2,"htmlHeader":"<!-- begin field 609c2db9-805e-4da9-a037-8eb42ebc6e78 --><h2>Nitrofurantoin</h2><!-- end field 609c2db9-805e-4da9-a037-8eb42ebc6e78 -->","summary":"","htmlStringContent":"<!-- begin item 7e58e554-4ff1-4eb1-9df2-703b15d3fa81 --><!-- end item 7e58e554-4ff1-4eb1-9df2-703b15d3fa81 -->","topic":{"id":"991f627d-8926-57b4-aaf8-67af4fd5db9d","topicId":"510a3aa0-27ac-462a-a52b-fe6491d08ab0","topicName":"Urinary tract infection - children","slug":"urinary-tract-infection-children","lastRevised":"Last revised in February 2019","chapters":[{"id":"d1ecfd05-b7d6-5f26-958b-08cbc3d78492","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5867e1c1-3817-541e-8b04-bef811c2f6c4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"79d4f794-da69-53db-a658-5ce7c959f692","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2f77533f-9993-5dbe-aec4-d0ee486a2559","slug":"changes","fullItemName":"Changes"},{"id":"79054143-84a5-50b1-8bcd-34d7ea4ff7da","slug":"update","fullItemName":"Update"}]},{"id":"26055421-3310-5e60-9152-68faccc1b450","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2e0770ba-47ca-5e33-8ed4-cc1f3f27b080","slug":"goals","fullItemName":"Goals"},{"id":"9b22c988-34f6-555d-9dc3-8ab3bb093e3a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fe1b7a61-e520-56e2-be30-8608881cdb7f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2b6a45d0-fdcd-5821-864d-63a74db81d6a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6f051e1-15a3-55a3-be65-2a623b2dae1c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8b4bab45-57e8-59b8-bd66-9036dc2fc571","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"dd9ffb6c-bd87-54d5-8c87-1e080e01ea4b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"1136e250-9882-5b2e-a75c-91e52993494f","slug":"definition","fullItemName":"Definition"},{"id":"45b0687c-19a3-5dc0-a5aa-e56c1e8d1061","slug":"causal-organisms","fullItemName":"Causal organisms"},{"id":"003daae9-bb06-5297-8ac5-cabcf10e7968","slug":"prevalence","fullItemName":"Prevalence"},{"id":"750a5b3e-7655-5653-bd66-cbf33a4daffe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"2d85acf8-d02b-5815-bb49-4c5f17b8678f","slug":"prognosis","fullItemName":"Prognosis"},{"id":"9f9d006d-bcda-5469-81d7-d2c3123c99d4","slug":"complications","fullItemName":"Complications"}]},{"id":"0bd6000e-bd4c-5f90-a711-bd23da73865d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8f91b779-7c82-5647-b2f7-d8c90726d303","slug":"suspecting-a-urinary-tract-infection","fullItemName":"Suspecting a urinary tract infection"},{"id":"5e82d0e6-4bfb-58c7-955f-7d2bc44d7ff6","slug":"diagnosing-a-urinary-tract-infection","fullItemName":"Diagnosing a urinary tract infection"},{"id":"57282b06-7213-5787-8603-4673c4ead4c4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d3a08393-35d5-53dc-935a-d5e32abee30b","fullItemName":"Management","slug":"management","subChapters":[{"id":"732454b5-6086-54ad-8fe0-68d4d8c9b5f8","slug":"uti-in-children","fullItemName":"Scenario: UTI in children"},{"id":"47d251fa-94da-5df5-889b-aec47b266935","slug":"recurrent-uti-in-children","fullItemName":"Scenario: Recurrent UTI in children"}]},{"id":"fcc5959a-b3b9-5135-9a34-0567f5ec597e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"49e814b6-1bc7-5c87-91e7-ea6edc49413f","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"178d0dc1-f68e-5c02-8ab6-590182cdb89b","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin"},{"id":"f0eecb36-6697-52c3-ba61-43722573d661","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"32a374c4-43e1-56a3-bc3a-3750191e085c","slug":"amoxicillin","fullItemName":"Amoxicillin"}]},{"id":"8b665f09-70b4-5fb0-a6c8-77c4766fc268","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1d405e7c-5e75-5615-8deb-94bb5f1d64cb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"82284d2f-4c04-573e-861c-5f030553a063","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"27e92d92-08e0-5fd8-aa0b-a5d456171c04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3afd108c-e35b-5034-9573-81cf33f52df5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ce068350-baea-5cb3-9040-ab2a90e020f8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e6c46138-9934-5c77-9727-4d36f784738d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"46eac86e-96b0-524a-ac9a-887b17be1e1c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fcc5959a-b3b9-5135-9a34-0567f5ec597e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"9ee2e131-c7db-575b-a119-f0b76f8f5f7e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field fb816fae-c854-4417-9248-a82a01247758 --><h3>Contraindications and cautions</h3><!-- end field fb816fae-c854-4417-9248-a82a01247758 -->","summary":"","htmlStringContent":"<!-- begin item 0a670625-c78f-4e1a-a300-a82a012472bf --><!-- begin field 4af19419-8e4f-4043-ad84-a82a01247758 --><ul><li><strong>Do not prescribe nitrofurantoin in children aged less than 3 months, or children with:</strong><ul><li>Acute porphyria.</li><li>Renal impairment — estimated glomerular filtration rate (eGFR) less than 45 mL/minute/1.73 m<sup>2</sup>.<ul><li>A short course of up to 7 days may be used if the eGFR is 30–44 mL/minute/1.73 m<sup>2</sup> and a urinary tract infection has suspected or proven multi-drug resistance, when the benefits of nitrofurantoin are considered to outweigh the risks of adverse effects.</li></ul></li><li>Glucose-6-phosphate dehydrogenase deficiency.</li></ul></li><li><strong>Prescribe nitrofurantoin with caution in people with:</strong><ul><li>Anaemia, diabetes mellitus, electrolyte imbalance, debilitating conditions, and vitamin B or folate deficiency.</li><li>Peripheral neuropathy or susceptibility to peripheral neuropathy —<strong> </strong>treatment should be stopped at the first signs of neural involvement (paraesthesiae).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">BNF 76, 2018</a>]</p><!-- end field 4af19419-8e4f-4043-ad84-a82a01247758 --><!-- end item 0a670625-c78f-4e1a-a300-a82a012472bf -->","subChapters":[]},{"id":"ce242826-8c72-5a2d-b3e8-cd06feb9ad41","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 819dafc2-e407-4dc0-9dde-a82a01249487 --><h3>Adverse effects</h3><!-- end field 819dafc2-e407-4dc0-9dde-a82a01249487 -->","summary":"","htmlStringContent":"<!-- begin item 6bc1d5da-6f2a-4f98-bd1d-a82a01249084 --><!-- begin field c64c2b79-20f3-4a6f-87ec-a82a01249487 --><ul><li><strong>Blood disorders</strong> — agranulocytosis, leucopenia, granulocytopenia, haemolytic anaemia, thrombocytopenia, megaloblastic anaemia, glucose-6-phosphate dehydrogenase deficiency anaemia, and eosinophilia (rare). </li><li><strong>Gastrointestinal </strong>— nausea, vomiting, abdominal pain, diarrhoea, anorexia, sialadenitis (frequency unknown).</li><li><strong>Hepatobiliary disorders </strong>— chronic hepatitis, cholestatic jaundice (rarely).</li><li><strong>Respiratory </strong>— acute pulmonary reactions may occur within the first week of treatment, and are manifested by fever, chills, cough, chest pain, dyspnoea, and eosinophilia. Reversible on stopping treatment.<ul><li><strong>Rarely:</strong> chronic pulmonary reactions occur in people who have received continuous therapy for six months or longer. It is more common in the elderly.</li></ul></li><li><strong>Nervous system </strong>— peripheral neuropathy, depression, euphoria, confusion, psychotic reactions, nystagmus, vertigo, dizziness, asthenia, headache and drowsiness, benign intracranial hypertension (frequency unknown).</li><li><strong>Skin </strong>— angioneurotic oedema, maculopapular, erythematous or eczematous eruptions, urticaria, rash, and pruritus.<ul><li><strong>Rarely: </strong>lupus-like syndrome, exfoliative dermatitis and erythema multiforme (including Stevens-Johnson Syndrome).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">BNF 76, 2018</a>]</p><!-- end field c64c2b79-20f3-4a6f-87ec-a82a01249487 --><!-- end item 6bc1d5da-6f2a-4f98-bd1d-a82a01249084 -->","subChapters":[]},{"id":"3c665898-0a6f-535c-a10b-23a2c17149fe","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 56ec79f0-573e-49e4-840c-a82a0124ec7e --><h3>Drug interactions</h3><!-- end field 56ec79f0-573e-49e4-840c-a82a0124ec7e -->","summary":"","htmlStringContent":"<!-- begin item 5f74ea69-f3ae-49b2-95de-a82a0124e868 --><!-- begin field feebd13d-2a08-4b8e-ace2-a82a0124ec7e --><ul><li><strong>Alkalinizing agents (such as potassium citrate)</strong> — the antibacterial activity of nitrofurantoin is reduced when the pH of the urine is increased. It may be prudent to avoid in people taking nitrofurantoin, however there is no evidence that this possible interaction presents a problem in practice.</li><li><strong>Magnesium trisilicate</strong> — absorption of nitrofurantoin may be reduced.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-children/references/\">BNF 76, 2018</a>]</p><!-- end field feebd13d-2a08-4b8e-ace2-a82a0124ec7e --><!-- end item 5f74ea69-f3ae-49b2-95de-a82a0124e868 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}